Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury
NCT07875322Phase 1Not yet recruiting
- Sponsor
- Assiut University
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 1, randomised trial of silymarin and acetylcysteine in drug induced liver injury (DILI) (3 arms), sponsored by Assiut University. Primary endpoint: Incidence of developing Anti-tuberculosis drug-induced liver injury (ATDILI) at 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
silymarinacetylcysteine
03
Conditions
drug induced liver injury (DILI)
Beyond the preview
Go deeper on NCT07875322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875322.